TY - JOUR T1 - Non-Whipple Operations in the Management of Benign, Premalignant and Early Cancerous Duodenal Lesions JF - Anticancer Research JO - Anticancer Res SP - 1443 LP - 1452 VL - 37 IS - 3 AU - ALEXANDROS PAPALAMPROS AU - DEMETRIOS MORIS AU - ATHANASIOS PETROU AU - NIKOLAOS DIMITROKALLIS AU - IOANNIS KARAVOKYROS AU - DIMITRIOS SCHIZAS AU - IOANNA DELLADETSIMA AU - THEODORE N. PAPPAS AU - EVANGELOS FELEKOURAS Y1 - 2017/03/01 UR - http://ar.iiarjournals.org/content/37/3/1443.abstract N2 - Aim: We reviewed our 20-year experience with non-Whipple operations (pancreas-preserving duodenectomy and transduodenal ampullectomy) for the treatment of benign, premalignant or early-stage malignant duodenal lesions. Patients and Methods: Twenty-four patients who underwent non-Whipple operations between January 1996 and December 2015 were identified from an institutional database and retrospectively analyzed. Results: Between 1996 and 2015, 10 patients underwent pancreas-preserving duodenectomy and 14 patients underwent transduodenal ampullectomy. The mean follow-up was 25.8 months (range=6-54 months) and no patient was lost to follow-up. Eighteen patients had preoperative diagnosis of duodenal adenomatosis, three patients had preoperative diagnosis of duodenal adenocarcinoma, one had a bleeding polyp and two had localized inflammation. Average operative time was 145 min (range=127-168 min) for transduodenal ampullectomy and 183 min (range=173-200 min) for pancreas-preserving duodenectomy (p<0.05). The estimated blood loss for transduodenal ampullectomy was 85 vs. 125 ml for pancreas-preserving duodenectomy (p<0.05). Early postoperative complications were noted in 13 cases (54.17%). There were no postoperative (90-day) deaths observed in this series and there were no recurrences during follow-up for the patients operated on with neoplastic lesions. Conclusion: For carefully selected patients, transduodenal ampullectomy and pancreas-preserving duodenectomy may be used in place of the Whipple operation for benign and occasionally early-stage malignant (Tis and T1) duodenal and ampullary disease. ER -